AIM
IOVA icon

ARK Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

ARK Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-775,787
Closed -$5.46M – 228
2023
Q2 		$5.46M Sell
775,787
-33,179
-4% -$237K 0.04% 123
2023
Q1 		$4.94M Sell
808,966
-10,898
-1% -$75.2K 0.03% 124
2022
Q4 		$5.24M Sell
819,864
-1,497,353
-65% -$11.7M 0.05% 124
2022
Q3 		$22.2M Sell
2,317,217
-618,462
-21% -$7.13M 0.15% 80
2022
Q2 		$19.8M Sell
2,935,679
-101,764
-3% -$1.33M 0.12% 93
2022
Q1 		$50.6M Sell
3,037,443
-4,164,075
-58% -$64.4M 0.21% 69
2021
Q4 		$137M Sell
7,201,518
-4,448,319
-38% -$97.9M 0.42% 46
2021
Q3 		$287M Sell
11,649,837
-6,800,876
-37% -$160M 0.69% 36
2021
Q2 		$480M Sell
18,450,713
-1,275,937
-6% -$33.2M 0.89% 30
2021
Q1 		$625M Buy
19,726,650
+4,428,828
+29% +$184M 1.24% 23
2020
Q4 		$710M Buy
15,297,822
+7,394,514
+94% +$294M 1.89% 13
2020
Q3 		$260M Buy
7,903,308
+3,668,035
+87% +$112M 1.54% 19
2020
Q2 		$116M Buy
4,235,273
+3,348,094
+377% +$110M 1.25% 24
2020
Q1 		$26.6M Buy
887,179
+63,835
+8% +$1.69M 0.66% 33
2019
Q4 		$22.8M Buy
823,344
+8,548
+1% +$194K 0.57% 38
2019
Q3 		$14.8M Buy
814,796
+7,108
+0.9% +$157K 0.32% 50
2019
Q2 		$19.8M Buy
807,688
+116,194
+17% +$1.75M 0.5% 40
2019
Q1 		$6.58M Sell
691,494
-34,866
-5% -$339K 0.19% 60
2018
Q4 		$6.43M Buy
726,360
+301,540
+71% +$2.91M 0.26% 53
2018
Q3 		$4.78M Buy
424,820
+302,197
+246% +$4.29M 0.14% 70
2018
Q2 		$1.57M Buy
122,623
+57,527
+88% +$841K 0.06% 95
2018
Q1 		$1.1M Buy
+65,096
New +$986K 0.05% 100

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ARK Investment Management's IOVA Position: Q3 2023 in Review

ARK Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 775,787 shares — an estimated $5.46M sold.

ARK Investment Management first reported a position in IOVA in Q1 2018 and held it in 22 quarters. The position peaked at $710M in Q4 2020. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • ARK Investment Management reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • ARK Investment Management sold 775,787 Iovance Biotherapeutics shares in Q3 2023, an estimated $5.46M.
  • ARK Investment Management first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 22 quarters.
  • ARK Investment Management's Iovance Biotherapeutics position peaked at $710M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on ARK Investment Management's 13F filing for Q3 2023, filed 18 Oct 2023.